SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio ...

• Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein standards and affinity reagents position the organizations to probe disease-associated proteof ...

Core Insights - Nautilus Biotechnology, Inc. has launched an Early Access Program for its novel proteomics platform, featuring a tau proteoforms assay aimed at accelerating Alzheimer's and neurodegenerative disease research [1][3][4] Group 1: Early Access Program - The Early Access Program allows select researchers to utilize Nautilus' Iterative Mapping method for protein analysis, enhancing the study of diseases like Alzheimer's [1][3] - Participants will receive support from Nautilus for data interpretation and analysis, facilitating rapid adoption and actionable insights [3][4] Group 2: Iterative Mapping Method - Nautilus' Iterative Mapping method enables single-molecule analysis of proteins, achieving comprehensive proteome coverage and detail, which is crucial for understanding post-translational modifications in diseases [2][4] - This method provides a high level of resolution, uncovering biological insights that traditional proteomics methods cannot achieve [2] Group 3: Commercialization and Research Collaboration - The Early Access Program marks a significant step towards commercialization, showcasing the platform's readiness for external use and future capabilities in proteomics [3][4] - Researchers at the Buck Institute for Research on Aging are already utilizing Nautilus' technology to map distinct tau proteoforms, revealing patterns associated with disease progression [5] Group 4: Custom Assays and Future Developments - The program also offers opportunities for exclusive development partnerships to create custom assays tailored to specific research needs [6] - Nautilus plans to host a webinar to discuss the benefits of Iterative Mapping and present updated research data, further promoting its platform [7]

Core Insights - Nautilus Biotechnology, Inc. has successfully deployed its first external field evaluation unit at the Buck Institute, generating tau proteoform data that validates its single-molecule proteomics platform [1][2][4] - The collaboration aims to explore tau proteoforms' role in neurodegeneration and cognitive decline, with initial findings to be presented at the 2025 HUPO World Congress [3][6] - The instrument's performance demonstrates high reproducibility and readiness for broader research applications, particularly in studying Alzheimer's disease [4][5] Company Overview - Nautilus is a development stage life sciences company focused on creating a platform for quantifying and understanding the complexity of the proteome [7][8] - The company's mission is to democratize access to proteomics, enabling advancements in human health and medicine [8] Research Collaboration - The ongoing collaboration with the Buck Institute leverages Nautilus' Proteome Analysis Platform to investigate the functional variants of tau protein associated with Alzheimer's disease [3][5] - The joint efforts have shown that the tau assay can generate reproducible data across different research settings, establishing a foundation for future studies [4][5]

Financial Performance - For the three months ended September 30, 2025, net loss was $13,574,000, a decrease from a net loss of $16,446,000 for the same period in 2024, reflecting an improvement of about 17.0%[19] - The net loss for the three months ended September 30, 2025, was $13.6 million, a reduction of 17% compared to a net loss of $16.4 million in the prior year[107] - Net loss for the nine months ended September 30, 2025, was $45.2 million, a decrease of $7.966 million, or 15%, from a net loss of $53.2 million in 2024[111] - The accumulated deficit as of September 30, 2025, was $318.2 million, reflecting significant losses primarily from research and development activities[93] - The company incurred net losses of $13.6 million and $45.2 million during the three and nine months ended September 30, 2025, respectively, compared to losses of $16.4 million and $53.2 million during the same periods in 2024[169] Assets and Liabilities - As of September 30, 2025, total assets decreased to $200,915,000 from $242,743,000 as of December 31, 2024, representing a decline of approximately 17.3%[18] - Total stockholders' equity decreased to $169,139,000 as of September 30, 2025, from $208,730,000 at the end of 2024, a decline of about 18.9%[18] - The company’s total liabilities decreased to $31,776,000 as of September 30, 2025, from $34,013,000 at the end of 2024, a reduction of approximately 6.6%[18] - Cash and cash equivalents at the end of the period were $24,877,000, compared to $5,411,000 at the end of September 30, 2024, showing a significant increase[26] - The company had cash, cash equivalents, and short-term investments totaling $131.4 million as of September 30, 2025, which is expected to fund operations for at least the next twelve months[32] Research and Development - Research and development expenses for the nine months ended September 30, 2025, were $31,535,000, down from $37,654,000 in 2024, indicating a reduction of approximately 16.3%[19] - For the three months ended September 30, 2025, research and development expenses were $9.6 million, a decrease of 22% from $12.3 million in the same period in 2024[108] - Research and development expenses decreased by $6.1 million, or 16%, to $31.5 million for the nine months ended September 30, 2025, compared to $37.7 million in 2024[112] Operating Expenses - The company reported total operating expenses of $51,413,000 for the nine months ended September 30, 2025, down from $61,496,000 in 2024, a decrease of approximately 16.4%[19] - The total operating expenses for the three months ended September 30, 2025, were $15.472 million, down from $19.100 million in the same period of 2024, indicating a decrease of approximately 19%[81] - General and administrative expenses for the same period were $5.9 million, down 14% from $6.8 million in 2024[109] - General and administrative expenses decreased by $4.0 million, or 17%, to $19.9 million for the nine months ended September 30, 2025, compared to $23.8 million in 2024[113] Cash Flow - The company experienced a net cash used in operating activities of $38,321,000 for the nine months ended September 30, 2025, compared to $44,836,000 in 2024, reflecting an improvement of approximately 14.6%[26] - Net cash used in operating activities was $38.3 million for the nine months ended September 30, 2025, compared to $44.8 million in 2024[127] - Net cash provided by investing activities was $34.4 million for the nine months ended September 30, 2025, compared to $29.1 million in 2024[131] Future Outlook and Risks - The company expects to require substantial additional funding to support ongoing research and development and commercialization efforts[94] - The company may need to seek additional equity or debt financing if its capital resources are exhausted sooner than expected[32] - The company expects to continue incurring significant losses and negative cash flows for the foreseeable future, alongside substantial legal, accounting, and other expenses as a public company[169] - The company may need to raise additional capital to fund its development and commercialization plans[157] - The company is facing compliance issues with Nasdaq regarding the minimum bid price requirement and has applied for a transfer to the Nasdaq Capital Market[121] Commercialization Strategy - The company plans to launch early access to its proteomics platform in the first half of 2026, focusing on the analysis of the Tau protein associated with Alzheimer's disease[1] - The commercialization strategy includes a three-phase plan, with the third phase anticipated to lead to a broader commercial launch in late 2026[1] - The broader commercial launch of the Nautilus platform is expected in late 2026, with subsequent consumable releases aimed at meeting or exceeding previously announced product specifications[171] Market and Competitive Landscape - The life sciences technology market is highly competitive, with major competitors including Thermo Fisher Scientific and Bruker Corporation, which may have advantages in resources and market presence[192][193] - The company faces challenges in achieving broad scientific and market acceptance of its products and services, which could impact revenue recognition[170] - Market acceptance of the Nautilus platform will be influenced by the ability to demonstrate reliable performance and justify the anticipated costs[180] Funding and Capital Needs - A shelf registration statement was filed allowing for equity and debt offerings up to $300 million, with a prospectus supplement covering the sale of up to $125 million of common stock[216] - The ability to raise additional funds may be adversely impacted by worsening global economic conditions and volatility in credit and financial markets[216] - The company is exploring various funding options, including equity, convertible debt, credit facilities, and other debt financing[212]

Financial Data and Key Metrics Changes - For Q3 2025, total operating expenses were $15.5 million, down from $19.1 million in Q3 2024, reflecting a 19% year-over-year decrease [17] - Research and development expenses decreased to $9.6 million from $12.3 million year-over-year, driven by lower development costs and improved operating efficiency [17] - General and administrative expenses were $5.9 million, down from $6.8 million in Q3 2024, largely due to reduced stock compensation expense [17] - Net loss for the quarter was $13.6 million, compared to $16.4 million in the prior year period [17] - Cash burn in Q3 was $11.0 million, benefiting from lower operating expenses, with a cash runway projected to extend through 2027 [18][19] Business Line Data and Key Metrics Changes - The company is advancing its TAU proteoform assay and plans to launch an early access program in the first half of 2026 [21] - The early access program will initially focus on TAU, with plans to expand to broad-scale proteomic capabilities in the second half of 2026 [27] Market Data and Key Metrics Changes - The company completed a market study involving over 250 decision-makers across North America and Europe, confirming strong interest in the Nautilus platform [14] - Customers view the Nautilus platform as uniquely differentiated from current technologies, with a strong willingness to invest in its solutions [15] Company Strategy and Development Direction - Nautilus Biotechnology is focused on commercialization and has made significant progress in scientific, platform, and operational priorities [4] - The company aims to validate its platform through early access programs and collaborations with leading research institutions [9][21] - The strategic goal includes launching a broad-scale assay configuration to support commercial activities by late 2026 [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the platform's potential to reshape the proteomics landscape, supported by extensive market research [22] - The company anticipates increased operating expenses as it approaches commercialization, with a steady ramp-up expected through 2027 [25][19] Other Important Information - The company is preparing to showcase externally generated TAU data at the World HUPO Conference in November, marking a significant milestone [21] - Nautilus is experiencing increased interest from partners eager to explore new disease areas and proteoform targets [8] Q&A Session Summary Question: What is the expected level of OpEx investment heading into the launch next year? - Management indicated that spending will increase as the company approaches commercialization, with cash projected to last through 2027 [25] Question: Can you elaborate on the funnel being built ahead of early access? - The company plans to launch the early access program in the first half of 2026, starting with TAU, and will expand to broad-scale capabilities in the second half of 2026 [27][29]

Financial Data and Key Metrics Changes - Total operating expenses for Q3 2025 were $15.5 million, down from $19.1 million in Q3 2024, reflecting a 19% year-over-year decrease [17] - Net loss for the quarter was $13.6 million, compared to $16.4 million in the prior year period [17] - Cash burn in Q3 was $11.0 million, benefiting from lower operating expenses, with a cash balance of $168.5 million at the end of the quarter [18] Business Line Data and Key Metrics Changes - Research and development expenses for Q3 2025 were $9.6 million, down from $12.3 million a year ago, driven by lower development costs and improved operating efficiency [17] - General and administrative expenses were $5.9 million, down from $6.8 million in Q3 2024, largely due to reduced stock compensation expense [17] Market Data and Key Metrics Changes - The company completed an extensive market study involving over 250 decision makers across North America and Europe, confirming strong interest in the Nautilus platform [14][15] - Customers expressed a willingness to pay a premium for the Nautilus solution, valuing it on par with high-end mass spectrometry systems [15] Company Strategy and Development Direction - The company is focused on launching an early access program in the first half of 2026, starting with the Tau proteoform assay [9][21] - The strategy includes expanding the early access program to include broad-scale proteomic capabilities in the second half of 2026 [27] - The company aims to build credibility and operational readiness ahead of the commercial launch through early engagements [9][20] Management's Comments on Operating Environment and Future Outlook - Management highlighted the importance of collaborations with leading research institutions to validate the platform's capabilities and drive biological insights [8][21] - The company anticipates that total operating expenses for the full year 2025 will be below the levels seen in the past two years, with Q3 expected to be a low point in spending [19] Other Important Information - The company is transitioning to a new broad-scale assay configuration to improve platform performance and align with its growing probe library [10] - The first public presentation of externally generated Tau data measured on the Nautilus platform is scheduled for the Human Proteome Organization's World HUPO Conference in November [6] Q&A Session Summary Question: How should the level of OpEx investment be considered heading into the launch next year? - Management indicated that spending is expected to increase as commercialization approaches, with cash projected to last through 2027 [25] Question: Can you elaborate on the funnel being built ahead of early access? - The company plans to launch the early access program with Tau capabilities in the first half of 2026, followed by broad-scale capabilities in the second half [27][28]

Financial Data and Key Metrics Changes - For Q3 2025, total operating expenses were $15.5 million, down from $19.1 million in Q3 2024, reflecting a 19% year-over-year decrease [17] - Research and development expenses decreased to $9.6 million from $12.3 million a year ago, driven by lower development costs and improved operating efficiency [17] - General and administrative expenses were $5.9 million, down from $6.8 million in Q3 2024, largely due to reduced stock compensation expense [17] - Net loss for the quarter was $13.6 million, compared to $16.4 million in the prior year period [17] - Cash burn in Q3 was $11.0 million, benefiting from lower operating expenses, with a cash runway projected to extend through 2027 [18] Business Line Data and Key Metrics Changes - The company is advancing its TAU proteoform assay and plans to launch an early access program in the first half of 2026 [21] - Collaborations with institutions like the Buck Institute for Research on Aging and the Allen Institute for Brain Science are expanding, indicating a growing interest in the company's platform [8][9] Market Data and Key Metrics Changes - A market study involving over 250 decision-makers across North America and Europe confirmed that customers view the Nautilus platform as uniquely differentiated from current technologies [14] - Customers expressed a willingness to pay a premium for the Nautilus solution, valuing it on par with high-end mass spectrometry systems [15] Company Strategy and Development Direction - The company is focused on transitioning to a new broad-scale assay configuration to improve platform performance and align with its growing probe library [10] - The early access program will initially focus on the TAU proteoform assay, with plans to expand to broader proteomic capabilities later [26] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of operational discipline and expense management, which has led to a strong balance sheet and a clear line of sight to strategic goals [21] - The company is confident in its technology and the commercial opportunity ahead, supported by extensive market research [22] Other Important Information - The company is preparing to showcase externally generated TAU data at the World HUPO Conference in November, marking a significant milestone [21] - The Nautilus platform is seen as a disruptive technology that delivers insights that existing technologies cannot match [22] Q&A Session Summary Question: OpEx investment level heading into the launch next year - Management anticipates that operating expenses will increase as the company approaches commercialization, with cash projected through 2027 [25] Question: Details on the funnel being built ahead of early access - The early access program will launch with the TAU proteoform assay, followed by broader capabilities in the second half of the year, with ongoing discussions to build the pipeline for both products [26][27]

Core Insights - Nautilus Biotechnology, Inc. reported financial results for Q3 2025, highlighting progress towards commercialization of its proteome analysis platform by late 2026 [1][3]. Financial Performance - Operating expenses for Q3 2025 were $15.5 million, a 19% decrease from $19.1 million in Q3 2024, attributed to operational efficiencies and reduced development costs [4]. - The net loss for Q3 2025 was $13.6 million, improved from a net loss of $16.4 million in the same period last year [4]. - As of September 30, 2025, cash, cash equivalents, and investments totaled $168.5 million [5]. Business Developments - The company is focused on launching an early access program for Tau proteoforms in the first half of 2026, which is a critical step towards full commercial availability [3][9]. - Continued progress was made in processing Tau proteoform samples, supporting product validation and increasing publications [9]. - Development of a new broadscale assay format is underway, aimed at supporting the commercial launch planned for late 2026 [9].

Financial Performance - Operating expenses for Q3 2025 were $15.5 million, a 19% decrease from $19.1 million in Q3 2024[4] - Net loss for Q3 2025 was $13.6 million, compared to a net loss of $16.4 million in the same period last year[4] - The company reported a net loss per share of $0.11 for Q3 2025, compared to $0.13 for Q3 2024[13] Assets and Liabilities - Cash, cash equivalents, and investments totaled $168.5 million as of September 30, 2025[5] - Total current assets increased to $134.3 million as of September 30, 2025, compared to $132.8 million at the end of 2024[12] - Total liabilities decreased to $31.8 million as of September 30, 2025, from $34.0 million at the end of 2024[12] - Total stockholders' equity decreased to $169.1 million as of September 30, 2025, from $208.7 million at the end of 2024[12] Research and Development - Research and development expenses for Q3 2025 were $9.6 million, down from $12.3 million in Q3 2024[13] - The company plans to launch an early access program for Tau proteoforms in the first half of 2026[8] - The company expects to share data on Tau proteoform samples at the upcoming World HUPO conference[8]